Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy -
Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy.
G Ital Dermatol Venereol. 2020 Dec;155(6):733-738. doi: 10.23736/S0392-0488.18.06117-5. Epub 2018 Sep 24.
Psoriasis is a chronic, recurrent, and immune-mediated inflammatory disease that affects 2-3% of the world population. A substantial proportion of patients with psoriasis, approximately 40%, develop a form of inflammatory arthritis known as psoriatic arthritis (PsA), the arthritis follows the development of psoriasis, and it will develop simultaneously or possibly before the appearance of skin lesions. The presence of PsA indicates a need for more active intervention rather than purely topical therapies or UV-based therapies. The aim of this multicenter, retrospective, epidemiological study was to estimate the incidence of PsA in psoriatic patients receiving UV treatment as monotherapy.
A retrospective epidemiological study was performed in 8 dermatological reference center, located throughout Italy (2 from Northern, 3 from Center, 3 from Southern); a period of 1 year was considered. Data from the overall study population including 326 patients with a diagnosis of psoriasis were analyzed. Furthermore, data coming from follow-up visits, including screening for PsA onset through specific questionnaires were analyzed.
PsA screening was positive in 27 patients (8.3%), whereas PsA diagnosis was confirmed by a rheumatologist in only 22/27 (81.5%) being therefore found in 22/326 (6.7%). Patients diagnosed with PsA had a statistically significantly higher abdominal circumference (96±15.3 vs. 88.9±18.3, P=0.048) and more commonly presented a positive past medical history for phototherapy (90.9% vs. 57.6% P=0.004).
Our study showed that phototherapy is not able to prevent or slow down the risk of PsA development in psoriatic patients. PsA screening should be always carried out in those patients even if asymptomatic, especially in obese subjects which are at great risk to develop PsA due to their increased systemic inflammatory state.
银屑病是一种慢性、复发性和免疫介导的炎症性疾病,影响全球 2-3%的人口。大约 40%的银屑病患者会出现一种称为银屑病关节炎(PsA)的炎症性关节炎,关节炎伴随着银屑病的发展,它会同时或可能在皮肤损伤出现之前发展。PsA 的存在表明需要更积极的干预,而不仅仅是单纯的局部治疗或基于 UV 的治疗。这项多中心、回顾性、流行病学研究的目的是估计接受 UV 单一疗法治疗的银屑病患者中 PsA 的发病率。
在意大利各地的 8 个皮肤科参考中心(2 个来自北部,3 个来自中心,3 个来自南部)进行了一项回顾性流行病学研究;考虑了 1 年的时间。对包括 326 例银屑病诊断患者在内的整个研究人群的数据进行了分析。此外,还分析了随访访问的数据,包括通过特定问卷筛查 PsA 发病情况。
27 例(8.3%)筛查出 PsA 阳性,而仅有 22/27(81.5%)例经风湿病学家确诊为 PsA,因此在 22/326(6.7%)例中发现。确诊为 PsA 的患者的腰围有统计学显著增加(96±15.3 与 88.9±18.3,P=0.048),并且更常见有光疗阳性既往病史(90.9% 与 57.6%,P=0.004)。
我们的研究表明,光疗不能预防或减缓银屑病患者 PsA 发展的风险。即使无症状,也应始终对这些患者进行 PsA 筛查,尤其是那些因全身性炎症状态增加而处于发生 PsA 高风险的肥胖患者。